-
Navigating the Maize: Cyclic and conditional computational graphs for molecular simulation
Authors:
Thomas Löhr,
Michael Dodds,
Lili Cao,
Mikhail Kabeshov,
Michele Assante,
Jon-Paul Janet,
Marco Klähn,
Ola Engkvist
Abstract:
Many computational chemistry and molecular simulation workflows can be expressed as graphs. This abstraction is useful to modularize and potentially reuse existing components, as well as provide parallelization and ease reproducibility. Existing tools represent the computation as a directed acyclic graph (DAG), thus allowing efficient execution by parallelization of concurrent branches. These syst…
▽ More
Many computational chemistry and molecular simulation workflows can be expressed as graphs. This abstraction is useful to modularize and potentially reuse existing components, as well as provide parallelization and ease reproducibility. Existing tools represent the computation as a directed acyclic graph (DAG), thus allowing efficient execution by parallelization of concurrent branches. These systems can, however, generally not express cyclic and conditional workflows. We therefore developed Maize, a workflow manager for cyclic and conditional graphs based on the principles of flow-based programming. By running each node of the graph concurrently in separate processes and allowing communication at any time through dedicated inter-node channels, arbitrary graph structures can be executed. We demonstrate the effectiveness of the tool on a dynamic active learning task in computational drug design, involving the use of a small molecule generative model and an associated scoring system.
△ Less
Submitted 22 January, 2024;
originally announced February 2024.
-
Utilizing Reinforcement Learning for de novo Drug Design
Authors:
Hampus Gummesson Svensson,
Christian Tyrchan,
Ola Engkvist,
Morteza Haghir Chehreghani
Abstract:
Deep learning-based approaches for generating novel drug molecules with specific properties have gained a lot of interest in the last few years. Recent studies have demonstrated promising performance for string-based generation of novel molecules utilizing reinforcement learning. In this paper, we develop a unified framework for using reinforcement learning for de novo drug design, wherein we syst…
▽ More
Deep learning-based approaches for generating novel drug molecules with specific properties have gained a lot of interest in the last few years. Recent studies have demonstrated promising performance for string-based generation of novel molecules utilizing reinforcement learning. In this paper, we develop a unified framework for using reinforcement learning for de novo drug design, wherein we systematically study various on- and off-policy reinforcement learning algorithms and replay buffers to learn an RNN-based policy to generate novel molecules predicted to be active against the dopamine receptor DRD2. Our findings suggest that it is advantageous to use at least both top-scoring and low-scoring molecules for updating the policy when structural diversity is essential. Using all generated molecules at an iteration seems to enhance performance stability for on-policy algorithms. In addition, when replaying high, intermediate, and low-scoring molecules, off-policy algorithms display the potential of improving the structural diversity and number of active molecules generated, but possibly at the cost of a longer exploration phase. Our work provides an open-source framework enabling researchers to investigate various reinforcement learning methods for de novo drug design.
△ Less
Submitted 30 January, 2024; v1 submitted 30 March, 2023;
originally announced March 2023.
-
Industry-Scale Orchestrated Federated Learning for Drug Discovery
Authors:
Martijn Oldenhof,
Gergely Ács,
Balázs Pejó,
Ansgar Schuffenhauer,
Nicholas Holway,
Noé Sturm,
Arne Dieckmann,
Oliver Fortmeier,
Eric Boniface,
Clément Mayer,
Arnaud Gohier,
Peter Schmidtke,
Ritsuya Niwayama,
Dieter Kopecky,
Lewis Mervin,
Prakash Chandra Rathi,
Lukas Friedrich,
András Formanek,
Peter Antal,
Jordon Rahaman,
Adam Zalewski,
Wouter Heyndrickx,
Ezron Oluoch,
Manuel Stößel,
Michal Vančo
, et al. (22 additional authors not shown)
Abstract:
To apply federated learning to drug discovery we developed a novel platform in the context of European Innovative Medicines Initiative (IMI) project MELLODDY (grant n°831472), which was comprised of 10 pharmaceutical companies, academic research labs, large industrial companies and startups. The MELLODDY platform was the first industry-scale platform to enable the creation of a global federated mo…
▽ More
To apply federated learning to drug discovery we developed a novel platform in the context of European Innovative Medicines Initiative (IMI) project MELLODDY (grant n°831472), which was comprised of 10 pharmaceutical companies, academic research labs, large industrial companies and startups. The MELLODDY platform was the first industry-scale platform to enable the creation of a global federated model for drug discovery without sharing the confidential data sets of the individual partners. The federated model was trained on the platform by aggregating the gradients of all contributing partners in a cryptographic, secure way following each training iteration. The platform was deployed on an Amazon Web Services (AWS) multi-account architecture running Kubernetes clusters in private subnets. Organisationally, the roles of the different partners were codified as different rights and permissions on the platform and administrated in a decentralized way. The MELLODDY platform generated new scientific discoveries which are described in a companion paper.
△ Less
Submitted 12 December, 2022; v1 submitted 17 October, 2022;
originally announced October 2022.
-
Autonomous Drug Design with Multi-Armed Bandits
Authors:
Hampus Gummesson Svensson,
Esben Jannik Bjerrum,
Christian Tyrchan,
Ola Engkvist,
Morteza Haghir Chehreghani
Abstract:
Recent developments in artificial intelligence and automation support a new drug design paradigm: autonomous drug design. Under this paradigm, generative models can provide suggestions on thousands of molecules with specific properties, and automated laboratories can potentially make, test and analyze molecules with minimal human supervision. However, since still only a limited number of molecules…
▽ More
Recent developments in artificial intelligence and automation support a new drug design paradigm: autonomous drug design. Under this paradigm, generative models can provide suggestions on thousands of molecules with specific properties, and automated laboratories can potentially make, test and analyze molecules with minimal human supervision. However, since still only a limited number of molecules can be synthesized and tested, an obvious challenge is how to efficiently select among provided suggestions in a closed-loop system. We formulate this task as a stochastic multi-armed bandit problem with multiple plays, volatile arms and similarity information. To solve this task, we adapt previous work on multi-armed bandits to this setting, and compare our solution with random sampling, greedy selection and decaying-epsilon-greedy selection strategies. According to our simulation results, our approach has the potential to perform better exploration and exploitation of the chemical space for autonomous drug design.
△ Less
Submitted 20 January, 2023; v1 submitted 4 July, 2022;
originally announced July 2022.
-
Implications of Topological Imbalance for Representation Learning on Biomedical Knowledge Graphs
Authors:
Stephen Bonner,
Ufuk Kirik,
Ola Engkvist,
Jian Tang,
Ian P Barrett
Abstract:
Adoption of recently developed methods from machine learning has given rise to creation of drug-discovery knowledge graphs (KG) that utilize the interconnected nature of the domain. Graph-based modelling of the data, combined with KG embedding (KGE) methods, are promising as they provide a more intuitive representation and are suitable for inference tasks such as predicting missing links. One comm…
▽ More
Adoption of recently developed methods from machine learning has given rise to creation of drug-discovery knowledge graphs (KG) that utilize the interconnected nature of the domain. Graph-based modelling of the data, combined with KG embedding (KGE) methods, are promising as they provide a more intuitive representation and are suitable for inference tasks such as predicting missing links. One common application is to produce ranked lists of genes for a given disease, where the rank is based on the perceived likelihood of association between the gene and the disease. It is thus critical that these predictions are not only pertinent but also biologically meaningful. However, KGs can be biased either directly due to the underlying data sources that are integrated or due to modeling choices in the construction of the graph, one consequence of which is that certain entities can get topologically overrepresented. We demonstrate the effect of these inherent structural imbalances, resulting in densely-connected entities being highly ranked no matter the context. We provide support for this observation across different datasets, models as well as predictive tasks. Further, we present various graph perturbation experiments which yield more support to the observation that KGE models can be more influenced by the frequency of entities rather than any biological information encoded within the relations. Our results highlight the importance of data modeling choices, and emphasizes the need for practitioners to be mindful of these issues when interpreting model outputs and during KG composition.
△ Less
Submitted 18 March, 2022; v1 submitted 13 December, 2021;
originally announced December 2021.
-
Parallel Capsule Networks for Classification of White Blood Cells
Authors:
Juan P. Vigueras-Guillén,
Arijit Patra,
Ola Engkvist,
Frank Seeliger
Abstract:
Capsule Networks (CapsNets) is a machine learning architecture proposed to overcome some of the shortcomings of convolutional neural networks (CNNs). However, CapsNets have mainly outperformed CNNs in datasets where images are small and/or the objects to identify have minimal background noise. In this work, we present a new architecture, parallel CapsNets, which exploits the concept of branching t…
▽ More
Capsule Networks (CapsNets) is a machine learning architecture proposed to overcome some of the shortcomings of convolutional neural networks (CNNs). However, CapsNets have mainly outperformed CNNs in datasets where images are small and/or the objects to identify have minimal background noise. In this work, we present a new architecture, parallel CapsNets, which exploits the concept of branching the network to isolate certain capsules, allowing each branch to identify different entities. We applied our concept to the two current types of CapsNet architectures, studying the performance for networks with different layers of capsules. We tested our design in a public, highly unbalanced dataset of acute myeloid leukaemia images (15 classes). Our experiments showed that conventional CapsNets show similar performance than our baseline CNN (ResNeXt-50) but depict instability problems. In contrast, parallel CapsNets can outperform ResNeXt-50, is more stable, and shows better rotational invariance than both, conventional CapsNets and ResNeXt-50.
△ Less
Submitted 6 September, 2021; v1 submitted 5 August, 2021;
originally announced August 2021.
-
Understanding the Performance of Knowledge Graph Embeddings in Drug Discovery
Authors:
Stephen Bonner,
Ian P Barrett,
Cheng Ye,
Rowan Swiers,
Ola Engkvist,
Charles Tapley Hoyt,
William L Hamilton
Abstract:
Knowledge Graphs (KG) and associated Knowledge Graph Embedding (KGE) models have recently begun to be explored in the context of drug discovery and have the potential to assist in key challenges such as target identification. In the drug discovery domain, KGs can be employed as part of a process which can result in lab-based experiments being performed, or impact on other decisions, incurring sign…
▽ More
Knowledge Graphs (KG) and associated Knowledge Graph Embedding (KGE) models have recently begun to be explored in the context of drug discovery and have the potential to assist in key challenges such as target identification. In the drug discovery domain, KGs can be employed as part of a process which can result in lab-based experiments being performed, or impact on other decisions, incurring significant time and financial costs and most importantly, ultimately influencing patient healthcare. For KGE models to have impact in this domain, a better understanding of not only of performance, but also the various factors which determine it, is required. In this study we investigate, over the course of many thousands of experiments, the predictive performance of five KGE models on two public drug discovery-oriented KGs. Our goal is not to focus on the best overall model or configuration, instead we take a deeper look at how performance can be affected by changes in the training setup, choice of hyperparameters, model parameter initialisation seed and different splits of the datasets. Our results highlight that these factors have significant impact on performance and can even affect the ranking of models. Indeed these factors should be reported along with model architectures to ensure complete reproducibility and fair comparisons of future work, and we argue this is critical for the acceptance of use, and impact of KGEs in a biomedical setting.
△ Less
Submitted 23 May, 2022; v1 submitted 17 May, 2021;
originally announced May 2021.
-
A Review of Biomedical Datasets Relating to Drug Discovery: A Knowledge Graph Perspective
Authors:
Stephen Bonner,
Ian P Barrett,
Cheng Ye,
Rowan Swiers,
Ola Engkvist,
Andreas Bender,
Charles Tapley Hoyt,
William L Hamilton
Abstract:
Drug discovery and development is a complex and costly process. Machine learning approaches are being investigated to help improve the effectiveness and speed of multiple stages of the drug discovery pipeline. Of these, those that use Knowledge Graphs (KG) have promise in many tasks, including drug repurposing, drug toxicity prediction and target gene-disease prioritisation. In a drug discovery KG…
▽ More
Drug discovery and development is a complex and costly process. Machine learning approaches are being investigated to help improve the effectiveness and speed of multiple stages of the drug discovery pipeline. Of these, those that use Knowledge Graphs (KG) have promise in many tasks, including drug repurposing, drug toxicity prediction and target gene-disease prioritisation. In a drug discovery KG, crucial elements including genes, diseases and drugs are represented as entities, whilst relationships between them indicate an interaction. However, to construct high-quality KGs, suitable data is required. In this review, we detail publicly available sources suitable for use in constructing drug discovery focused KGs. We aim to help guide machine learning and KG practitioners who are interested in applying new techniques to the drug discovery field, but who may be unfamiliar with the relevant data sources. The datasets are selected via strict criteria, categorised according to the primary type of information contained within and are considered based upon what information could be extracted to build a KG. We then present a comparative analysis of existing public drug discovery KGs and a evaluation of selected motivating case studies from the literature. Additionally, we raise numerous and unique challenges and issues associated with the domain and its datasets, whilst also highlighting key future research directions. We hope this review will motivate KGs use in solving key and emerging questions in the drug discovery domain.
△ Less
Submitted 26 November, 2021; v1 submitted 19 February, 2021;
originally announced February 2021.
-
Application of generative autoencoder in de novo molecular design
Authors:
Thomas Blaschke,
Marcus Olivecrona,
Ola Engkvist,
Jürgen Bajorath,
Hongming Chen
Abstract:
A major challenge in computational chemistry is the generation of novel molecular structures with desirable pharmacological and physiochemical properties. In this work, we investigate the potential use of autoencoder, a deep learning methodology, for de novo molecular design. Various generative autoencoders were used to map molecule structures into a continuous latent space and vice versa and thei…
▽ More
A major challenge in computational chemistry is the generation of novel molecular structures with desirable pharmacological and physiochemical properties. In this work, we investigate the potential use of autoencoder, a deep learning methodology, for de novo molecular design. Various generative autoencoders were used to map molecule structures into a continuous latent space and vice versa and their performance as structure generator was assessed. Our results show that the latent space preserves chemical similarity principle and thus can be used for the generation of analogue structures. Furthermore, the latent space created by autoencoders were searched systematically to generate novel compounds with predicted activity against dopamine receptor type 2 and compounds similar to known active compounds not included in the training set were identified.
△ Less
Submitted 21 November, 2017;
originally announced November 2017.
-
Molecular De Novo Design through Deep Reinforcement Learning
Authors:
Marcus Olivecrona,
Thomas Blaschke,
Ola Engkvist,
Hongming Chen
Abstract:
This work introduces a method to tune a sequence-based generative model for molecular de novo design that through augmented episodic likelihood can learn to generate structures with certain specified desirable properties. We demonstrate how this model can execute a range of tasks such as generating analogues to a query structure and generating compounds predicted to be active against a biological…
▽ More
This work introduces a method to tune a sequence-based generative model for molecular de novo design that through augmented episodic likelihood can learn to generate structures with certain specified desirable properties. We demonstrate how this model can execute a range of tasks such as generating analogues to a query structure and generating compounds predicted to be active against a biological target. As a proof of principle, the model is first trained to generate molecules that do not contain sulphur. As a second example, the model is trained to generate analogues to the drug Celecoxib, a technique that could be used for scaffold hop** or library expansion starting from a single molecule. Finally, when tuning the model towards generating compounds predicted to be active against the dopamine receptor type 2, the model generates structures of which more than 95% are predicted to be active, including experimentally confirmed actives that have not been included in either the generative model nor the activity prediction model.
△ Less
Submitted 29 August, 2017; v1 submitted 25 April, 2017;
originally announced April 2017.
